Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.27
- Piotroski Score 3.00
- Grade Buy
- Symbol (PYXS)
- Company Pyxis Oncology, Inc.
- Price $3.93
- Changes Percentage (3.42%)
- Change $0.13
- Day Low $3.73
- Day High $3.93
- Year High $6.85
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $10.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.37
- Trailing P/E Ratio -2.77
- Forward P/E Ratio -2.77
- P/E Growth -2.77
- Net Income $-73,790,000
Income Statement
Quarterly
Annual
Latest News of PYXS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$25m market cap decline as longer-term profits stay in the green
Ownership research and analyst forecasts provide insights into stock opportunities. Pyxis Oncology, Inc. (NASDAQ: PYXS) is primarily owned by institutions, with key shareholders like Pfizer Inc. and h...
By Yahoo! Finance | 4 months ago
